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difference in effectiveness of drug therapy and surgery or between surgery types 
for carotid stenosis patients.
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Objectives: Comparative effectiveness research (CER) methods guides have 
recently been released by two main CER funding agencies, the Agency for Healthcare 
Research and Quality (AHRQ) and the Patient-Centered Outcomes Research Institute 
(PCORI). We evaluated and compared these methods guides to identify consensus 
in recommended CER methodologies. MethOds: CER methods recommendations 
from each document were assessed and areas of overlap were identified. Results: 
The PCORI Methodology Report (November 2013) made 40 CER methods recommen-
dations. The AHRQ User Guide (January 2013) made 57 CER methods recommenda-
tions. These methods recommendations related to the following 10 methods topics: 
study protocol and design, patient-centeredness, heterogeneity of treatment effect 
(HTE), causal inference, diagnostic tests, systematic reviews, comparator selection, 
study variables, data concerns, and statistical analysis. Of the 57 specific recom-
mendations made in the AHRQ guide, 24 (42%) were also made in the PCORI guide. 
For example, both documents support identifying gaps in evidence, explaining 
specific impacts of the research, developing a formal study protocol, and assess-
ing the adequacy of data sources. Furthermore, these documents both support 
rigorous measurement and analysis of confounders, precisely defining exposures 
and outcomes, and pre-specification of data analysis plans. Both documents also 
supported the selection of appropriate comparators and identifying and assess-
ing participant subgroups. Non-overlapping recommendations mostly addressed 
more specific methodology topics and issues including missing data, data regis-
tries, data networks, and patient-centeredness. These unique recommendations 
highlight areas for further debate and discussion regarding best practices in CER 
methods. cOnclusiOns: Based upon our synthesis of CER methods recommenda-
tions, agreement was high between the AHRQ and PCORI guides. We identified a list 
of core CER recommendations based on the overlap of these two methods guides 
which may aid researchers in the conduct of CER.
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Objectives: Medical device utilization and price are often cited as major cost 
drivers of hospital care. Few sources quantify the specific % medical device spend 
(utilization x price) of hospital care. The purpose of this study was to assess the 
contribution of medical device spending in the hospital setting, as well as the impact 
of hospital facility type on medical device spending. MethOds: A third party ven-
dor, MOSS Adams (Seattle, WA) compiled data from the 2009 U.S. Healthcare Cost 
Report Information system (HCRIS). HCRIS data is reported by providers through 
Medicare Administrative Contractors. The cost report contains information such as 
facility characteristics, utilization data, cost and charges by cost center (all payers). 
5,452 hospitals reported medical device spending costs with total expenditures of 
approximately $681 billion dollars. Costs were divided into implant costs, billable 
supply costs, labor, capital, and all other costs including infrastructure. Total medical 
device costs were estimated from implant and billable supply costs. Stratification 
included teaching/non-teaching, sole-community/ non-sole, and urban/rural hospi-
tals. Results: Labor and other costs represented the largest expenditure, whereas 
total medical device costs represented 3.6% (median) of costs. Urban hospitals spent 
more than rural hospitals on medical devices (5.5% vs. 2.3%, p< 0.0001). Teaching 
hospitals also spent more than non-teaching hospitals on medical devices (6.2% 
vs. 3.1%, p< 0.0001). There were no differences in medical device spend for sole 
community/non-sole community hospitals (3.6% each). When reviewing a subset of 
hospitals (n= 644) reporting on implantable medical device use, median total medical 
device spend was 7.1% including 3.5% on medical device implants. cOnclusiOns: 
These data suggest that total spending on medical devices, including implantables 
in the hospital setting represents a small spend of overall hospital expenditures. 
Future studies should examine the role of medical device utilization in overall hos-
pital expenditures.
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Objectives: Transcatheter aortic valve implantation (TAVI) is a treatment option 
for patients with severe symptomatic aortic stenosis ineligible for surgical treat-
ment (AVR). However, the role of TAVI in patients who are potential surgical can-
didates remains controversial and its cost-effectiveness has only been assessed 
using data from one single randomized trial. We sought to estimate the cost-
utility of the two existing transfemoral TAVI modalities (Edwards SAPIEN (ES) and 
Objectives: To compare the post-cessation weight gain following the use of 
different FDA-approved smoking cessation medication strategies among obese 
smokers. MethOds: A retrospective cohort study was conducted using the 
General Electric (GE) electronic medical record database (2006 – 2011). The cohort 
consisted of obese adult smokers newly initiating use of an FDA-approved smok-
ing cessation medication. The outcome variable was weight change at 3, 6, or 12 
months following the first prescription. Descriptive analyses and t-tests were 
conducted to assess the frequency distribution of sample characteristics and their 
association with the post-cessation weight change. Multivariate linear regression 
models were carried out to identify predictors of weight change at 3, 6, and 12 
months after assessing the model assumptions, with the use of multiple impu-
tation to account for missing data for covariates. Results: The mean weight 
change was 1.14 (±17.26), 2.06 (±18.46), and 3.06 pounds (±20.78) at 3-, 6-, and 
12-month, respectively. Obese smokers who were prescribed varenicline had a 
mean weight gain of 1.18 (±16.75), 2.14 (±18.14), and 3.12 pounds (±20.89) for each 
follow up, while those who were prescribed bupropion had a mean weight gain 
of 0.23 (±25.90), 0.22 (±25.32), and 1.47 pounds (±17.50), respectively. Descriptive 
analysis showed that obese smokers taking bupropion had less weight gain than 
those taking varenicline at each follow up; however, this association was not 
statistically significant after accounting for all covariates (β = -1.16 [-3.84 – -1.53] 
month 3; β = -3.16 [-6.54 – -0.21] month 6; β = -0.18 [-3.92 – 3.55] month 12). 
Significant predictors of weight change included: being diagnosed with diabe-
tes, hyperlipidemia, taking weight-influencing medications, and smoked > = one 
cigarette/day. cOnclusiOns: While patients using bupropion gained slightly less 
weight compared to those using varenicline, type of smoking cessation medica-
tion was not a significant predictor of weight change in the multivariate linear 
regression model.
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Objectives: Several single arm phase III trials have recently completed or are cur-
rently ongoing in various HCV patient populations. The goal of this study is to use 
meta-analysis to determine the rates of sustained virologic response 24 weeks after 
treatment (SVR24) required for a new HCV treatment to declare superiority over 
standard of care (SOC) in the setting of a single arm trial where there is no network 
of treatment arms that can bridge between the new treatment and SOC. MethOds: 
We conducted a literature search for studies of standard dose peginterferon-alfa 
plus ribavirin (IFNα +R) as well as telaprevir (TPV) or boceprevir plus IFNα +R among 
HCV-infected adults and synthesized the results by performing a meta-analysis 
based on a Bayesian hierarchical model. We then introduce hypothetical single arm 
trials into the meta-analysis and determine the efficacy relative to SOC. Benchmarks 
are the SVR24 rates required to have at least a 95% probability of superiority to 
SOC. Results: Benchmarks for a new treatment studied in a single arm trial of 
400 patients relative to TPV+IFNα +R are 84%, 72%, and 54% in genotype 1a or 88%, 
78%, and 62% in genotype 1b across treatment naïve, previous partial respond-
ers, and previous null responders respectively. Benchmarks for a new treatment 
studied in a single arm trial of 200 treatment naive patients relative to IFNα +R are 
91%, 88%, and 69% in genotypes 2, 3, and 4 respectively. Benchmarks were insensi-
tive to the sample size of the single arm trial. cOnclusiOns: Our meta-analysis 
method extends indirect treatment comparison methodology to make comparative 
effectiveness inference for treatments studied in single arm phase III trials. Our 
broad based meta-analysis platform is flexible enough to make inference across 
patient populations.
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bAckgROund: Randomized clinical trials comparing surgery to drug therapy in 
newly diagnosed carotid stenosis patients, are less relevant today with advance-
ment in drug therapy and increased utilization. Effectiveness of surgery versus 
current drug therapy in carotid artery stenosis patients hasn`t been studied in real 
world practice. Objectives: Compare time to death and other cerebrovascular 
events in newly diagnosed patients treated with carotid endarterectomy (CEA), 
carotid stenting (CAS) or drug therapy MethOds: Patients were identified using 
the Humana dataset for the years 2007 – 2012. The date of first diagnosis of carotid 
stenosis is set as the patient’s index date if followed by a confirmatory carotid 
duplex ultrasound. An episode of treatment consisted of the 6 months prior to and 
12 months post index date. Propensity score matching was employed to match 
patients using drug therapy to surgery patients. Surgery patients using CAS or CEA 
were matched separately. Cox proportional hazards models and logistic regres-
sion were used to estimate the impact of surgery versus medications, and surgery 
type using only surgery patients. Outcomes were defined as time to death and 
time to stroke or other cerebrovascular event. Results: 103,703 newly diagnosed 
patients were identified over age 50. A total of 4921 patients received surgery of 
which 476 died (9.7%). Of the 98,782 patients who received only drug therapy, 
7395 died (7.4%). Initial Cox and logistic models of death using the propensity 
score matched samples found no statistically significant risk associated with 
surgery versus medical management. Similarly, we found no statistically 
significant effects of CAS vs CEA in patients treated with a surgical interven-
tion. cOnclusiOns: Current clinical studies suggest stand-alone drug ther-
apy as treatment of choice. Initial analysis of this study suggests no real world 
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A3
rEsEArCh on modElinG mEthods studiEs
mo1
A unifiEd frAmEWork for ClAssifiCAtion of mEthods for bEnEfit-risk 
AssEssmEnt
Najafzadeh M.1, Schneeweiss S.1, Choudhry N.K.1, Bykov K.1, Kahler K.2, Martin D.2,  
Arcona S.2, Rogers J.R.1, Gagne J.J.1
1Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA, 2Novartis 
Pharmaceuticals Corporation, East Hanover, NJ, USA
Objectives: Patients, physicians, and other decision-makers make implicit trade-
offs among benefits and risks of different treatments. Many methods have been 
proposed to conduct quantitative benefit-risk analysis (BRA). We propose a frame-
work for classifying BRA methods based on factors that matter most to patients. 
Using common mathematical notation, we compare the methods using a hypo-
thetical example. MethOds: We classified available BRA methods into three cat-
egories: (1) un-weighted metrics, that use only probabilities of benefits and risks 
(e.g., number needed to treat and number needed to harm [NNT|NNH]); (2) metrics 
that incorporate preference weights to account for the impact and duration of out-
comes (e.g., Maximum Acceptable Risk [MAR], relative value-adjusted life-years 
[RVALYs], quality-adjusted life-years [QALYs]); and (3) metrics that incorporate 
ad hocweights based on decision makers’ opinions (e.g., Multi-criteria Decision 
Analysis, Benefit-Less-Risk Analysis). We used two hypothetical antiplatelet drugs 
(A and B), probabilities of benefits (reduction in myocardial infarction and stroke) 
and harms (increases in major and minor bleeding) based on randomized trial data, 
and preference weights from the literature to compare the BRA methods within 
the proposed framework. Results: Use of the framework and notation revealed 
BRA methods share substantial commonality. In the example, BRA using NNT|NNH 
indicated that -1.3% of patients would experience net benefit with drug A versus 
B, (an unfavorable benefit-risk balance for A). In contrast, 4.6% of patients would 
experience a net benefit with drug A if weighted using MAR. BRA using RVALYs and 
QALYs suggested gains of 3.8 RVALYs and 5.4 QALYs per 100 patient-years, respec-
tively, with drug A versus B. cOnclusiOns: The proposed framework provides 
a unified, patient-centered approach to BRA methods classification. All methods 
impose trade-offs between probabilities of benefits and risks. The weights used 
in the metrics is a key differentiating feature and can lead to quantitatively and 
qualitatively different results.
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Objectives: Network meta-analysis (NMA) is being increasingly used in the eco-
nomic evaluation of medical interventions. One potential advantage of NMA is that 
through stratified analysis it can allow comparison of treatments even when trial 
populations are not homogenous. Such analyses can then facilitate stratified cost 
effectiveness analysis (CEA). This is illustrated through the example of antithrom-
botic treatments for atrial fibrillation (AF) with stratification based on a clinical 
prediction rule (CHADS2). MethOds: Clinical trials in patients with non-valvular 
AF requiring anticoagulation were identified. A Bayesian mixed treatment compari-
son NMA was conducted for stroke, mortality, major bleeding, intracranial hemor-
rhage and myocardial infarction. Where available clinical trial data was obtained 
by CHADS2 score and analysis conducted within three sub groups (CHADS2 score 
< 2, = 2, > 2). Data for warfarin, apixaban, dabigatran 110mg and 150mg (twice daily), 
rivaroxaban, low and medium dose ASA, and clopidogrel plus ASA were available. 
A CEA stratified by CHADS2 score was conducted using a previously published eco-
nomic model. Results: For patients with a CHADS2 score < 2 and = 2, the incre-
mental cost utility ratio, ICUR for dabigatran 150mg versus warfarin was $20,845 
and $23,688 respectively: in both scenarios dabigatran 150mg dominated all other 
alternatives. For patients with a CHADS2 score > 2, the ICUR for apixaban versus 
warfarin was $2,402: apixaban dominated all other alternatives. cOnclusiOns: 
Based on current Canadian thresholds for cost effectiveness, dabigatran 150 mg 
bid was optimal for patients with a CHADS2 score < 2 and = 2, whilst apixaban was 
optimal for patients with a CHADS2 score > 2. This study highlights how NMA can 
be combined with stratified CEA to facilitate meaningful policy recommendations.
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Objectives: Recent legislation in Massachusetts promotes population health 
improvement while creating incentives to control health care costs. This research 
creates a tool that projects population health in order to predict health care use and 
spending, and to help policy makers make decisions about the allocation of health 
care resources. MethOds:  The Population Health Model is a micro-simulation that 
projects the health status and health care costs for Massachusetts residents over 
50. Drawing from the 1992-2010 Health and Retirement Study, we created modules 
for cancer, heart disease, COPD, diabetes, hypertension, stroke, and mortality risk 
using non-parametric survival analysis which adjusted for demographics, insurance 
status, smoking history, weight, and concurrent diseases. The model simulated indi-
vidual health trajectories over 5 years based on the 2011 state subset of Behavioral 
Risk Factor Surveillance System data. Results:  The model projected that for the 
Massachusetts 2011 cohort, starting disease prevalence rates were 13.5% for diabe-
tes, 42.9% for hypertension, 9.3% for heart disease, 10.6% for cancer, 8.2% for COPD, 
and 3.6% for stroke. Over 5 years, projected incidence rates for this population were 
Medtronic Corevalve (MC)) versus conventional surgery using data from “real-life” 
patients. MethOds: Prospective recruitment in 7 Spanish hospitals, with follow-
up at one, three and six months after intervention. We measured utility with EQ5D. 
We estimated crude and adjusted differences in costs and QALYs using regression 
analyses with bootstrap estimation of variance. We calculated incremental cost-
utility ratios (ICER) comparing ES and MC to AVR and derived cost-effectiveness 
acceptability curves. Subgroup and sensitivity analyses were performed. Results: 
Data from 48 ES-TAVI, 86 MC-TAVI and 52 AVR patients were analyzed; 4 were lost 
to follow up. Mean STS risk score was: ES: 4.9 (3), MC: 5.1 (3), AVR: 5.1 (2). Overall 
cost of ES-TAVI was 7,202 € higher than AVR (adjusted difference: 5,474; 95%CI: 926-
11,875) and the difference in QALYs was 0.045 (adjusted difference: 0.041; 95%CI: 
-0.015 – 0.96), resulting in an ICER of 161,086 € /QALY. The cost of MC-TAVI was 7,476 
€ higher than AVR (adjusted difference: 8,738; 95%CI: 4,480 – 12,997) and the differ-
ence in QALYs was 0.003 (adjusted difference: 0.025; 95%CI: -0.027 – 0.77), resulting 
in an ICER of 2,451,568 € /QALY. The results were mainly driven by the high cost of 
the TAVI device and did not substantially change in the sensitivity analysis and 
subgroups. cOnclusiOns: In the Spanish setting, the use of transfemoral TAVI 
when surgery is feasible is not likely to be cost-effective at a willingness-to-pay 
threshold of 30,000 € /QALY.
md3
AssEssinG WhEthEr “biG dAtA” solutions providE vAluE for 
diAGnostiCs mAnufACturErs
Hertz D., Gavaghan M., Garfield S.
GfK Market Access, Wayland, MA, USA
Objectives: Big data has the potential to provide tremendous value to health care 
manufacturers, improving their understanding of unmet clinical need and inform-
ing product development. The objective of this study was to analyze leading payer 
claims databases and EMR systems for diagnostic specific information and costs 
and to determine where unmet needs and opportunities for future data optimiza-
tion exist. MethOds: Five companies who sell large claims and EMR data sets were 
interviewed to understand costs and data granularity. Additionally, interviews were 
conducted with three diagnostic companies that recently purchased big data sets to 
better understand the opportunities and limitations of the data purchased related to 
diagnostic decision-making and research. Results: Datasets reviewed contained 
little granularity related to diagnostic tests. Specifically, because individual tests 
cannot be determined by CPT code, there was no way to determine the brand of 
test used or whether tests were FDA-approved or laboratory developed. Additionally, 
neither claims databases nor EMR systems capture the diagnostic platform used 
for laboratory analysis. There was variation in the detail contained in the databases 
related to lab results. EMR systems seemed to contain greater detail than claims 
system, but lack standards, making it hard to combine data sets. Diagnostic com-
panies are more likely than other health care manufacturers to be small compa-
nies with limited budgets. The current cost of purchasing data, excluding analysis, 
is estimated to be between $25,000 and $200,000. cOnclusiOns: Despite their 
potential, claims and EMR data sources have significant limitations in the detail 
they can provide related to diagnostic and lab services. Additionally, big data is not 
affordabile for many diagnostic companies. As a result, diagnostic companies face 
challenges in demonstrating both shortcomings of existing approaches and the 
clinical and cost utility of novel tests. As diagnostics become more central to health 
decision-making and personalized medicine, data sources need to address existing 
limitations to better demonstrate their clinical and economic impact.
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Objectives: Mitral regurgitation (MR), a cardiac disease resulting in volume 
overload, is associated with an increased risk of heart failure and mortal-
ity. Standard care for MR is surgical repair or replacement of the mitral valve. 
Patients at high risk for surgical intervention, such as those with functional MR, 
are often relegated to medical management alone. The MitraClip is a transcath-
eter device, which performs percutaneous edge-to-edge repair to treat MR. We, 
evaluated the real-world clinical and cost effectiveness of MitraClip in high-risk 
MR patients. MethOds: Data for patients receiving MitraClip were obtained 
from a prospective registry of high-risk MR patients treated at the Montreal Heart 
Institute (MHI) in Quebec from December 2010 to May 2013. These patients were 
propensity matched on baseline characteristics and medical therapy to medically 
treated MR patients followed at the MHI Heart Failure Clinic from 2008 to 2011. 
Cohorts were compared on clinical and economic outcomes, quality of life (QoL), 
complications/adverse events, emergency room (ER) visits, hospitalizations, 
surgical intervention, and clinic visits. Based on data from this matched com-
parison, we then developed a decision analytic model to assess the incremental 
cost-effectiveness of MitraClip vs. medical therapy in patients with high-risk 
MR. Survival for each group was extrapolated beyond follow-up to 10 years using 
Weibull regression. Unit costs were obtained from the MHI. Costs and benefits 
were discounted at 5% per annum. One-way and probabilistic sensitivity analyses 
were performed. Results: Compared with medical therapy, treatment with Mi-
traClip was associated with a gain of 1.34 quality-adjusted life years (QALYs) and 
an incremental cost of $48,970 (Canadian). The incremental cost-effectiveness 
ratio (ICER) was $36,543 per QALY gained. cOnclusiOns: Based on data from 
our matched, observational comparison, treatment with the MitraClip appears 
to be an economically attractive alternative to medical therapy for high-risk 
patients with MR.
